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the commercial monoclonal antibody. Collectively, we demon-
strate that the rationally designed small molecules can be potent
and specific drugs for anti-cancer therapy.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.006
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Numerous studies have shown that high-dose chemotherapy
and autologous hematopoietic stem cell transplantation (AHSCT)
led to a profound and long-lasting state of immunodeficiency
characterized by persisting low levels of T cells in hemoblastosis
patients. Well-timed T-cell reconstitution is crucial for early
restoration of anti-infectious and anti- tumor immune response.
Lymphocyte recovery is mediated through the two main mecha-
nisms – a homeostatic proliferation of T cells and generation of
new naive T cells via thymopoiesis. It is known, that homeostatic
proliferation is important for the restoration of T cell count in
immune competent host during the 1st year following AHSCT.
Thymus begins to fill up T cell repertoire approximately from
the 6th month following AHSCT.
We have investigated dynamics of CD4+FOXP3+ Treg recovery
following AHSCT and possible relationship between Tregs and
clinical outcomes since the suppressive activity of Tregs under
lymphopenic conditions may influence on peripheral expansion
of T cells. Thymic activity following AHSCT has been evaluated
by measuring amounts of CD4+ CD45RA+CD31+ naı¨ve T cells,
i.e. ‘‘recent thymic emigrants” (RTEs).109 patients with non-
Hodgkin’s lymphomas, Hodgkin’s lymphoma and multiple mye-
loma underwent AHSCT in 2009–2014. The content of circulating
CD4+FOXP3+ Tregs and CD4+CD45RA+CD31+ T cells was
evaluated using flow cytometry before AHSCT, at the day of
engraftment, and following 6 and 12 months.
Pre-transplant count of CD4+FOXP3+ Tregs was significantly
higher compared to healthy controls (5.4 ± 2.9 vs 3.8 ± 1.9%;
pU = 0.011; here and below data presented as Mean ± SD). Percent-
age of Tregs restored rapidly and reached initially high level at the
time of engraftment, and then subsequently decreased within a
year until it lowered to healthy donors‘ values. CD4+FOXP3+ Tregs
at the time of engraftment were increased in patients with
relapse or progression of disease within 6 and 12 months
following AHSCT compared to non-relapsed patients (11.0 ± 6.1
vs 6.2 ± 3.0%; pU = 0.016, and 10.1 ± 5.2 vs 6.1 ± 3.8%; pU = 0.008).
Pre-transplant count of CD4+CD45RA+CD31+ T cells was signifi-
cantly lower compared to healthy controls (17.1 ± 11.4 vs 30.3
± 11.2%, pU = 0.0005) and did not reach donors‘ values following
12 month (23.1 ± 13.5%, pU = 0.032). Relapsed patients had the
same quantity of RTEs as the patients with remission within
the 1st year following AHSCT. There was no any significant
association between RTEs and Tregs counts.
Surprisingly, we have found high levels of circulating CD4
+CD45RA- T cells co-expressing CD31 molecule in patients before
AHSCT, since this molecule is infrequent on memory subsets in
healthy controls (20.7 ± 12.0 vs 8.2 ± 2.1%,pU < 0.00001). Relative
amount of CD4+CD45RA-CD31+ T cells highly correlated with
CD4+CD45RO+CD31+ population (rS=0.72; p < 0.00001). The count
of CD4+CD45RA-CD31+ T cells recovered intensively and reached
the pre-transplant level within the 1st month following AHSCT,
and remained at the same level throughout the follow-up. There
were no any differences in relative count of CD4+CD45RA-CD31+
T cells between patients with early relapse and remission during
the 1st post-transplant year.
Our data of Tregs reconstitution may confirm the earlier
assumption that the presence of Tregs during the period of
immune recovery preserves optimal T cell receptors diversity.
However, the excess of these cells leads to the inhibition of
proliferative activity and immune response and is associated with
early relapse. Conversely, relatively slow recovery of RTEs
determines theirlack of influence on survival within the 1st
post-transplant year.
The biological role and the way of appearance of CD31
molecule on T cell memory subset (CD4+CD45RA- and/or CD4
+CD45RO+) still remain unclear. Further studies are required to
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Background: Gastric cancer (GC) remains one of the most
important gastrointestinal cancers worldwide. The incidence
and mortality rate from GC in Russia is higher in comparison with
other European countries and USA. It should be noted that
riskometry for the GC doesn’t exist. Parallel assessment of
pepsinogen I (PG I), pepsinogen II (PG II), PG I/PG II ratio and
gastrin-17 (G-17), as well as antibodies to Helicobacter pylori is an
exact and validated set of stomach-specific biomarkers that
reflect the extent and grade of gastric atrophy as a main prema-
lignant condition for GC.
Aim: To study the diagnostic and predicting value of
biomarkers of atrophic gastritis (AG) in retro-prospective cohort
case-control study in Siberian population.
Object and methods: General population sample was surveyed
in Novosibirsk in 2003–2005 (10.000 subjects aged 45–69 years).
Each serum sample was deeply frozen and stored. In 2008 and
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2012 this database was compared with the data of the Population
Cancer Registry. As a result of cross-sectional analysis of two
databases 60 novel cases of GC were identified until 2011. For each
case of GC, an appropriate control case was selected at the ratio
1:2 matching the area of residence, sex and age. Finally, 156
serum samples (52 – GC group and 104 – control group) were
available for the analysis using a panel of serum biomarkers
‘‘Gastropanel” (Biohit, Finland). Criteria for ‘‘Gastropanel” in the
diagnosis of AG were used: PG I <30lg/l, PG II <3lg/l, the ratio
PG I/PG II <3, the level of basal G-17<1 pmol/l, and the presence
of antibodies to H. pylori.
Results: Mean level of biomarkers did not differ between those
with, and without GC, with the exception for PG I/PGII ratio,
which was significantly lower in GC group. Indicators of gastric
atrophy (OR; 95% CI) were associated with GC for PG I (2.9;
1.3–6.4), PG II (9.0; 1.8–44.3), and PG I/PG II (3.3; 1.5–7.3), but
neither for G-17 (0.7, 0.4–1.6), nor for the presence of antibodies
to H. pylori (0.4; 0.1–1.3). Multivariate regression analysis
including sex, age of the patients, all biomarkers of ‘‘Gas-
tropanel” confirmed PG I and PGI/PGII ratio as the most powerful
indicators in the model. Atrophy Index (AI) was calculated as a
sum of abnormal parameters of gastric atrophy (PG I, PG I/PG II
ratio and G-17, see Table, *p < 0.019; **p < 0.006). AI 3 (all biomark-
ers below normal range) was more common in GC patients than
in controls.
Groups Severity of atrophy
(Atrophy Index score) (%)
3 2 1 0
Gastric cancer 14.0** 20.0 10.0 56.0
Control 2.2 10.8 11.8 75.3*
Conclusion: As a first step in the development of GC
riskometry was found that noninvasive set of serological
biomarkers is an informative and non-expensive tool for the
early detection of GC in population-based retrospective cohort
survey in Siberian population. Low levels of PGI and PGI/PGII
ratio were proven as the most valuable prognostic factors.
The low level of G-17 as a single index did not significantly
predict the risk of GC.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.008
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Background: Methylation systems in the cells play an impor-
tant role in the metabolic processes such as purine nucleotide
biosynthesis and gene and protein activity regulation. An imbal-
ance between entities in folic acid metabolism can adversely
affect nucleotide synthesis and the DNA repair and methylation
system, which can cause genome instability and impairments
in chromosome segregation, and lead to abnormal expression of
proto-oncogenes and inactivation of tumor suppressor genes.
These processes may underlie the development of a range of
cancer disease, including Non-Hodgkin’s lymphomas (NHL). Quite
a few studies investigating the association of SNPs in the
folate-metabolizing genes with NHL risk in populations of differ-
ent ethnic origin are available to date. Because the low prevalence
of this disease makes sampling difficult, most of these studies
have small sizes, which may be one of the reasons why results
obtained are often conflicting.
The aim of this study was to investigate the role of some SNPs
in folate genes (the C677T and A1298C SNPs in the MTHFR gene,
A2756G in MTR, A66G in SHMT1, G1958A in MTHFD1 and
844ins68 in CBS) in genetic susceptibility to non-Hodgkin’s
malignant lymphoma in the west-Siberian region.
Methods: 146 unrelated patients from the Haematological Cen-
ter (Novosibirsk city) with various types of NHL were investigated.
Genomic DNA was isolated from leukocytes in venous blood and
from buccal epithelium, using the standard methods of DNA sep-
aration. A PCR-restriction fragment length polymorphism (RFLP)
assay was used to detect the MTHFD1 G1958A and CBS 844ins68
SNPs. Genotyping of the MTHFR, MTR, MTRR and SHMT1 gene
SNPs was carried out by real-time PCR allelic discrimination with
TaqMan probes. The alleles and genotypes distribution of SNPs in
patients were compared with their distribution in healthy white
Russian subjects from Novosibirsk.
Results: We determined the allele and genotype frequencies for
seven SNPs in folate metabolism in NHL and control groups. For
all these SNPs, the genotype frequencies were in Hardy–Weinberg
equilibrium in the control group. There were no statistically
significant differences in the frequencies of alleles and genotypes
of polymorphic loci of MTHFR, MTRR, CBS, SHMT1 genes between
patients with NHL and controls. However, theG1958A MTHFD1
polymorphism showed a significant association with aggressive
NHL. The 1958A allele (OR = 0.578, C.I. [0.415–0.805], p < 0.001)
and AA MTHFD1 genotype (OR = 0.283, C.I. [0.130–0.613],
p < 0.0008) were associated with decreased risk of aggressive lym-
phoma. The association between folate genes and indolent non-
Hodgkin’s lymphoma was not revealed. The SNP G1958A causes
the Arg653Gln substitution occurring in the formyltetrahydrofo-
late domain of the MTHFD enzyme. The substrate for this enzyme
is tetrahydrofolate (THF). Potentially, the accumulation of THF
results in an increase in 5,10-methylenetetrahydrofolate concen-
tration, which in turn may enhance the efficiency of thymidylate
synthesis and DNA methylation. Together, these processes may
contribute to inhibition of malignant transformation.
Conclusion: G1958A SNP in the MTHFD1 gene contributes to
susceptibility to NHL. The mutant allele and genotype determine
the protective effect, probably, by affecting the concentration of
intracellular folic acid metabolites.
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